EMA holds its ground – certain obesity drugs must be removed from market

The European Medicines Agency’s risk assessment committee has confirmed its former recommendation to retract market approvals for weight-loss medicines based on amfepramone.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

The hopes of companies that want to continue selling obesity treatments containing active ingredient amfepramone in Europe may be dimming.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs